Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
Combination therapy shows promising progression-free survival in advanced non-small cell lung cancer patients with high PD-L1 expression
Early trial shows two-drug combo may help advanced lung cancer patients
This randomized phase 2 trial evaluated domvanalimab plus zimberelimab compared to zimberelimab alone or chemotherapy in patients with advan…
A Phase 2 trial suggests a two-drug combination might improve outcomes for some patients with advanced lung cancer compared to standard chem…
Evidence-based review of transducer selection for lung ultrasound in dogs and cats with pulmonary pathology
Choosing the right ultrasound probe can improve lung diagnoses for dogs and cats
This evidence-based review examines transducer selection for lung ultrasound in dogs and cats with pulmonary pathology.
Veterinary lung ultrasound accuracy depends on probe choice. This review highlights how transducer selection affects diagnosis in emergency …
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
Immune drugs boost survival in small-cell lung cancer
This systematic review and meta-analysis evaluates immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for ext…
Adding immune checkpoint inhibitors to chemotherapy helps patients with extensive-stage small-cell lung cancer live longer.
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Dry NaCl Inhalation Fails to Improve Mucociliary Clearance in COPD
Inhaled salt fails to clear mucus in COPD trial
This randomized, placebo-controlled crossover study in 25 patients with GOLD stage I-III COPD found that a single 40 mg dry NaCl inhalation …
Inhaling dry salt did not improve mucus clearance in COPD patients, a small trial finds. The study was cut short by COVID-19.
Review of animal models shows unclear causal links between microbial dysbiosis and pulmonary fibrosis
Your Gut Microbes May Shape Lung Fibrosis Treatment
This review examined animal models regarding pulmonary fibrosis.
Your gut microbes may influence lung scarring, opening new paths for treatment beyond current drugs.
Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients
Phase I trial shows subcutaneous tislelizumab reaches high drug levels in lung cancer patients
This phase I trial evaluated subcutaneous versus intravenous tislelizumab in treatment-naive patients with advanced non-small cell lung canc…
Early data suggest subcutaneous tislelizumab injections may offer similar drug levels to intravenous forms for treating advanced lung cancer…
RNK08954 shows unconfirmed responses in KRASG12D-mutant NSCLC and PDAC in Phase Ia trial
New drug shows promise for KRASG12D lung and pancreatic cancers
This phase Ia trial evaluated RNK08954 in 36 patients with KRASG12D-mutant non-small cell lung cancer or pancreatic ductal adenocarcinoma.
An early trial of RNK08954 shrank tumors in 58% of lung cancer patients with a specific KRAS mutation.
Pulmonary barotrauma incidence and risk factors in non-HIV PCP patients
Researchers find oxygen ratio predicts lung injury in pneumonia patients
This single-center retrospective cohort study of 334 non-HIV patients with Pneumocystis jirovecii pneumonia found that 12.0% developed pulmo…
A new model helps identify pneumonia patients at higher risk for severe lung complications using oxygen levels and blood markers.
LSTM analysis of infant tidal breathing detects bronchopulmonary dysplasia with 97% accuracy
New AI tool reads baby breath to spot lung disease early
This cohort study of 329 infants and 135 school-age children used recurrent neural networks to analyze tidal breathing flow time series.
A new computer model can read a baby's simple breathing pattern to find lung disease before it becomes serious.